The exemption will allow 3Spine to study its Motus device in a clinical trial, according to a June 22 news release. The company finished contracting and site initiation at 16 U.S. centers for a prospective study.
Motus is an implant used in the BalancedBack total joint replacement procedure. It is designed to address leg pain, back pain and spinal instability, 3Spine said.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
